News - Merck & Co, Oncology

Filter

Current filters:

Merck & CoOncology

Popular Filters

1 to 25 of 51 results

EMA accepts Merck’s pembrolizumab MAA for review

EMA accepts Merck’s pembrolizumab MAA for review

01-07-2014

US pharma giant Merck & Co says that the European Medicines Agency has accepted for review a Marketing…

EuropeMerck & CoOncologypembrolizumabPharmaceuticalRegulation

Positive data on Merck & Co’s nausea drug Emend Ph III trial in children

Positive data on Merck & Co’s nausea drug Emend Ph III trial in children

30-06-2014

Positive results have been announced by US pharma giant Merck & Co from a global, investigational Phase…

EmendMerck & CoOncologyPharmaceuticalRegulationResearch

Physicians views on EGFR wild-type/untested NSCLC treatment

Physicians views on EGFR wild-type/untested NSCLC treatment

20-06-2014

According to surveyed US and European oncologists, improvement in efficacy endpoints are the most influential…

AstraZenecaBiotechnologyBristol-Myers SquibbEuropeHealthcareMarkets & MarketingMerck & ConivolumabOncologyOno PharmaceuticalpembrolizumabselumetinibUSA

Merck & Co returns rights to Endocyte’s vintafolide

Merck & Co returns rights to Endocyte’s vintafolide

18-06-2014

Shares of USA-based Endocyte fell 19.7% to $6.20 in after-hours trading yesterday, after the company…

CisplatinEnd point of clinical trialsEndocyteHealth Medical PharmaLicensingMerck & CoOncologyPEGylationPharmaceuticalPlatinum-resistant ovarian cancervintafolide

Immunotherapies show promise for non-small cell lung cancer market

Immunotherapies show promise for non-small cell lung cancer market

13-06-2014

Immunotherapies have huge potential for the treatment of non-small cell lung cancer (NSCLC), with three…

BiotechnologyBristol-Myers SquibbMarkets & MarketingMerck & ConivolumabOncologypembrolizumabResearchRoche

Drug pricing power led by hepatitis C, diabetes and cancer

Drug pricing power led by hepatitis C, diabetes and cancer

13-06-2014

Hepatitis C, diabetes and cancer are sustaining high pricing power through innovation according to Morningstar's…

AbbVieAntibiotics and Infectious diseasesBiogen IdecCopaxoneDiabetesGenericsGilead SciencesMerck & CoOncologyPharmaceuticalPricingTecfideraTeva Pharmaceutical IndustriesUSA

Excitement as Merck releases new data on cancer drug candidate pembrolizumab

Excitement as Merck releases new data on cancer drug candidate pembrolizumab

03-06-2014

The findings released at the 2014 American Society of Clinical Oncology (ASCO) conference in Chicago…

Merck & CoOncologypembrolizumabPharmaceuticalResearch

Merck and Endocyte pull CMA for vintafolide and companion imaging component in EU

20-05-2014

US pharma giant Merck & Co and Endocyte have withdrawn their conditional marketing authorization applications…

EndocyteEuropeMerck & CoOncologyPharmaceuticalRegulationResearchvintafolide

Endocyte plummets on decision to stop vintafolide Ph III trial; posts financials

03-05-2014

US pharma giant Merck & Co and partner Endocyte revealed on Friday that the Data Safety Monitoring Board…

EndocyteFinancialMerck & CoOncologyPharmaceuticalResearchvintafolide

Merck & Co enters deal with Agenus worth a potential $100 million in milestones

Merck & Co enters deal with Agenus worth a potential $100 million in milestones

28-04-2014

USA-based biotech firm Agenus has entered into a collaboration and license agreement with pharma giant…

AgenusBiotechnologyLicensingMerck & CoOncologyResearch

EMA/CHMP backs approval of Merck ovarian cancer drug Vynfinit and companion diagnostics

21-03-2014

The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended…

EndocyteEuropeFolcepriMerck & CoNeocepriOncologyPharmaceuticalRegulationVynfinit

Pharma Summit: Merck’s European president Bruno Strigini highlights importance of innovation

Pharma Summit: Merck’s European president Bruno Strigini highlights importance of innovation

17-03-2014

The president of pharma giant Merck & Co’s (NYSE: MRK) operations in Europe and Canada Bruno Strigini…

Anti-viralsCanadaDiabetesEuropeInterviewsMerck & CoMK-3475OncologyPharmaceuticalRegulationUKVaccines

Merck returns rights to ridaforolimus to Ariad, whose 4th-qtr net loss widens

Merck returns rights to ridaforolimus to Ariad, whose 4th-qtr net loss widens

26-02-2014

US pharma giant Merck & Co has told partner Ariad Pharmaceutical that it is terminating its license agreement…

Ariad PharmaceuticalsFinancialLicensingMerck & CoOncologyPharmaceuticalridaforolimus

Advanced melanoma collaboration for Amgen and Merck & Co

Advanced melanoma collaboration for Amgen and Merck & Co

05-02-2014

World leading independent biotech firm Amgen and US pharma giant Merck & Co have entered into an agreement…

AmgenBiotechnologyMerck & CoMK-3475OncologyResearchtalimogene laherparepvec

Second research deal with Merck & Co for Ablynx

Second research deal with Merck & Co for Ablynx

03-02-2014

Belgian drugmaker Ablynx has entered into a second research collaboration and licensing agreement with…

AblynxLicensingMerck & CoOncologyPharmaceuticalResearch

Merck starts roll-out of BLA for MK-3475; vorapaxar FDA panel review

Merck starts roll-out of BLA for MK-3475; vorapaxar FDA panel review

14-01-2014

US drug giant Merck & Co says it has started a rolling submission to the US Food and Drug Administration…

Cardio-vascularMerck & CoMK-3475North AmericaOncologyPharmaceuticalRegulationUSAvorapaxarZontivity

Merck & Co trialing MK-3475 with GSK’s pazopanib in renal cancer

Merck & Co trialing MK-3475 with GSK’s pazopanib in renal cancer

18-12-2013

US pharma giant Merck & Co says it has initiated a clinical trial to evaluate the combination of the…

GlaxoSmithKlineMerck & CoMK-3475OncologyPazopanib TabletsPharmaceuticalResearch

Strong one-year results in patients with advanced melanoma treated with Merck’s MK-3475

Strong one-year results in patients with advanced melanoma treated with Merck’s MK-3475

19-11-2013

US pharma giant Merck & Co has announced additional data for MK-3475, an investigational anti-PD-1 immunotherapy,…

Merck & CoMK-3475OncologyPharmaceuticalResearch

New data on Merck and Endocyte’s vintafolide in ovarian cancer

New data on Merck and Endocyte’s vintafolide in ovarian cancer

15-10-2013

Merck & Co and partner Endocyte today announced the on-line publication of results from the randomized…

EndocyteMerck & CoOncologyPharmaceuticalResearchvintafolide

AstraZeneca gains rights to Merck ovarian cancer candidate

11-09-2013

Anglo-Swedish drug major AstraZeneca (LSE: AZN) and US pharma giant Merck & Co (NYSE: MRK) this morning…

AstraZenecaLicensingMerck & CoMK-1775OncologyPharmaceutical

BPH drug doesn't increase risk of death, but does save men from prostate cancer

15-08-2013

A long-term follow-up to a groundbreaking study led by the director of the Cancer Therapy & Research…

finasterideGenericsMen's HealthMerck & CoOncologyPharmaceuticalProscarResearch

Generic Temodar launches in USA

13-08-2013

Israel-headquartered Teva Pharmaceutical Industries (NYSE: TEVA) and Perrigo (NYSE: PRGO;TASE) today…

GenericsMarkets & MarketingMerck & CoNorth AmericaOncologyPerrigoTemodarTeva Pharmaceutical Industries

Melanoma market set to grow to more than $2.8 billion by 2021

05-07-2013

The branded melanoma drug market is set to grow to more than $2.8 billion across the USA and major European…

Bristol-Myers SquibblambrolizumabMarkets & MarketingMerck & CoOncologyPharmaceuticalYervoy

1 to 25 of 51 results

Company Spotlight

Eleven Biotherapeutics

Eleven Biotherapeutics

Back to top